top of page
The Professional Network for Healthcare Experts
Biocon and Genentech reach global Pebrilzo biosimilar patent settlement establishing launch dates
Biocon and Genentech have reached a global patent settlement and licence agreement establishing planned launch windows for Pebrilzo, Biocon's pertuzumab biosimilar to Perjeta.
nuaxia
Oct 152 min read
FDA approves Tukysa combination as first-line maintenance therapy for HER2-positive advanced breast cancer
The FDA has approved Pfizer's Tukysa in combination with trastuzumab and pertuzumab as a first-line maintenance treatment for adults with HER2-positive advanced breast cancer.
nuaxia
Oct 82 min read
European Commission approves Enhertu plus pertuzumab for first-line HER2-positive metastatic breast cancer
The European Commission has approved Enhertu plus pertuzumab as a first-line treatment for adults with unresectable or metastatic HER2-positive breast cancer.
nuaxia
Sep 22 min read
bottom of page